CBIONasdaqPharmaceutical PreparationsFiscal year ends December 31
CRESCENT BIOPHARMA, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 30, 2026
$12.36+0.52 (+4.39%)
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- –
- Dividend yield
- –
Crescent Biopharma statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | Crescent Biopharma | Industry median |
|---|---|---|
| Market Cap | $459.10M | $197.05M |
| Enterprise Value | $287.51M | $106.56M |
| PB Ratio | 2.81 | 2.14 |
| P/TBV Ratio | 2.81 | 2.46 |
Income (trailing twelve months)
| Measure | Crescent Biopharma | Industry median |
|---|---|---|
| Operating Income | -$168.47M | -$21.44M |
| Net Income | -$96.03M | -$22.46M |
| EBITDA | -$168.47M | -$16.91M |
Returns
| Measure | Crescent Biopharma | Industry median |
|---|---|---|
| Return on Equity (ROE) | -63.5% | -53.1% |
| Return on Assets (ROA) | -56.5% | -41.0% |
| Return on Capital Employed (ROCE) | -102.6% | -37.8% |
Growth
| Measure | Crescent Biopharma | Industry median |
|---|---|---|
| Revenue Growth (3Y CAGR) | 424.9% | 2.25% |
| Revenue Growth (5Y CAGR) | 1.31% | 6.42% |
Balance sheet
| Measure | Crescent Biopharma | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $171.59M | $62.42M |
| Net Cash (Debt) | $171.59M | $15.68M |
| Net Cash Per Share | $4.62 | $0.65 |
| Equity (Book Value) | $163.26M | $48.79M |
| Book Value Per Share | $4.40 | $1.36 |
| Tangible Book Value | $163.26M | $23.06M |
| Working Capital | $160.47M | $75.77M |
Financial position
| Measure | Crescent Biopharma | Industry median |
|---|---|---|
| Current Ratio | 9.66 | 3.30 |
| Quick Ratio | 9.26 | 2.39 |
Cash flow (trailing twelve months)
| Measure | Crescent Biopharma | Industry median |
|---|---|---|
| Operating Cash Flow | -$72.68M | -$12.35M |
| Capital Expenditures | -$939.00K | -$1.06M |
| Free Cash Flow | -$73.62M | -$20.28M |
| FCF Per Share | -$1.98 | -$0.41 |
Efficiency
| Measure | Crescent Biopharma | Industry median |
|---|---|---|
| Profits Per Employee | -$2.18M | -$732.08K |
| Employee Count | 44 | 73 |
Dividends and yields
| Measure | Crescent Biopharma | Industry median |
|---|---|---|
| Earnings Yield | -20.9% | -21.2% |
| FCF Yield | -16.0% | -7.64% |
Shares
| Measure | Crescent Biopharma | Industry median |
|---|---|---|
| Shares Outstanding | 37,143,900 | 59,128,900 |
| Shares Change (QoQ) | 0.67% | 0.54% |
| Float | 22,788,500 | 48,744,500 |
| Shares Held by Insiders | 38.6% | 11.8% |
| Shares Held by Institutions | 78.4% | 59.4% |
Taxes
| Measure | Crescent Biopharma | Industry median |
|---|---|---|
| Income Tax | $2.00M | $91.50K |
Scores
| Measure | Crescent Biopharma | Industry median |
|---|---|---|
| Altman Z-Score | 10.45 | 0.10 |
Calculated by StockData from Crescent Biopharma's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.